← Back to all trials
Recruiting
NCT06998706
REGEND001 Autologous Basal Layer Stem Cell Transplantation for Interstitial Lung Disease (ILD): A Translational Application Study
Conditions: Interstitial Lung Disease (ILD)
Sex: All
Ages: 40 Years – 75 Years
Healthy volunteers: No
Phase: PHASE1
Enrollment: 10
Sponsor: Ruijin Hospital
Location: Ruijin Hospital Hainan Branch, Shanghai Jiao Tong University School of Medicine Qionghai Hainan
Summary
This clinical trial evaluates the safety and efficacy of REGEND001, an autologous bronchial basal layer stem cell therapy, in patients with interstitial lung disease (ILD). The treatment involves harvesting the patient's own stem cells (expressing KRT5/P63 markers), expanding them ex vivo, and administering them via bronchoscopic infusion to regenerate damaged lung tissue.
Eligibility Criteria
Inclusion Criteria:
1. Age 40-75 years.
2. Confirmed diagnosis of ILD (e.g., IPF, connective tissue disease-associated ILD).
3. DLCO ≥30% and \
Source: ClinicalTrials.gov (NCT06998706). StuddyBuddy aggregates publicly available trial information.
